Investor Relations

Pitch video

pitch video – Windows Media player [94 MB]

pitch video – Apple Quicktime player [484 MB]

Pitch video

Who we are?

  • German Start-up, EMA SME Qualification EMA/SME/357/15/R1
  • To develop autologous (own) cord blood stem cell therapies in Europe/USA for the treatment of Pediatric brain injury
  • Our product was granted ATMP-TEP Classification by EMA

What do we do?

  • Develop and market (own) cord blood stem cell treatments for
  • The treatment of Pediatric brain injury
    • Periventricular leukomalacia
    • Neonatal encephalopathy
    • Perinatal intracranial hemorrhage
    • Pediatric stroke
    • Cerebral palsy
    • Spinal cord injury
    • Traumatic brain injury

What makes us unique?

What do we want?

  • We seek early access to the market and ‘market exclusivity’ granted by EMA based on our autologous ATMP-TEP product and Orphan drug designations.
  • Our ultimate goal is to provide for those in need early access to an autologous cord blood treatment for ailments for which there is no cure at present.
  • We invite investors to participate in an unprecidented therapeutic innovation – The future of brain repair is now!
  • New investors:
    • Family Office A&C, Germany
    • Professor M.R. Franz, M.D., PhD
      Georgetown University, Washington D.C., USA
      Entrepreneur, scientist, and founder

Is there a market in Europe?

What is the incidence of the disease each year?

  • 15,000 children suffer from Periventricular leukomalacia
  • 15,000 children suffer from Neonatal encephalopathy
  • 27,000 children suffer from Perinatal intracranial hemorrhage
  • 1,200 children suffer from Stroke
  • 10,000 children suffer from Cerebral palsy
  • 1,700 children suffer from Spinal cord injury (SCI)
  • 3,000 children suffer from Traumatic brain injury (TBI)

Is the treatment safe?

  • Worldwide approx. 387 children have been treated for brain disorders with autologous cord blood stem cells employing >500 infusions.
  • Due to the autologous nature of the cord blood treatment, no serious infusion related adverse events have been observed. Rarely, mild transient adverse events were noted (1.5%) (Sun et al., 2010).

References

  • Jensen A, (2014) “Autologous Cord Blood Therapy for Infantile Cerebral Palsy: From Bench to Bedside,“ Obstet Gynecol Int
    http://dx.doi.org/10.1155/2014/976321
  • Sun J et al., (2010) “Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders,” Transfusion, vol. 50, no. 9, pp. 1980–1987.